Galmed Pharmaceuticals (NASDAQ:GLMD) Research Coverage Started at StockNews.com

by · The Cerbat Gem

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report issued on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Up 2.5 %

Shares of GLMD opened at $0.28 on Thursday. Galmed Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $5.47. The firm has a market cap of $1.39 million, a price-to-earnings ratio of -0.11 and a beta of 0.80. The business’s 50 day moving average is $0.37 and its two-hundred day moving average is $0.37.

Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its quarterly earnings data on Thursday, May 30th. The biopharmaceutical company reported ($0.23) EPS for the quarter.

Galmed Pharmaceuticals Company Profile

(Get Free Report)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.

See Also